INTRODUCTION {#sec1-1}
============

Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) belonging to the family of propionics derived from arylcarboxylic acid with analgesic and antipyretic effects. It works by inhibiting cyclooxygenase 1 and 2 (COX 1 and COX 2) enzymes reversibly, which decreases the production of pro-inflammatory prostaglandin precursors. It is widely used in the management of inflammatory and musculoskeletal conditions, pain, and fever in children and adults.\[[@ref1]\]

From analysis of spontaneous reports of adverse events for the year 2008 in Italy, ketoprofen is the eleventh busiest with 206 reports of which about 30% are serious. A total of 13% of the reports were in charge of pediatric patients (age below 18 years), even in the range of age (\<6 years) in which drug is off-label.\[[@ref2]\] Data for the year 2012 are not completely available; however, preliminary statistics indicate that ketoprofen was involved in 560 ADRs of which 31% were serious (personal data).

The increase in reports of ketoprofen is due to an increase in the use of this NSAID after repeated warnings of hepatotoxicity in other European countries in relation to nimesulide.\[[@ref3]\] The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) has taken action to reduce the inappropriate use of nimesulide limiting its repeatable dispensing from recipe to recipe not repeatable (RNR). The sharp reduction in the consumption of this drug between 2007 and 2008 by approximately 40% resulted in an increase in the use of other NSAIDs, in particular ketoprofen (+52%), ibuprofen (+57%), and diclofenac (+18 %).

The known adverse events of ketoprofen include: cardiovascular reactions (peripheral edema), central (headache, drowsiness, etc.), dermatological (skin sensitization and photosensitization after topical use), blood (edema, platelet dysfunction, etc.), liver (increased liver enzymes), gastrointestinal (vomiting, diarrhea, ulcers, and bleeding in the stomach, etc.), ophthalmic, renal, respiratory (asthma), systemic (sweating, hives, etc.).

MATERIALS AND METHODS {#sec1-2}
=====================

All 17 ADRs reports regarding ketoprofen as suspected drug included in the national database in 2012 were analyzed. The Medline and PubMed library databases were searched for papers published until June 2013 for related side effects and papers reporting the safety and use of ketoprofen. Searches were initially conducted to identify all studies extracted from the database using Ketoprofen and safety as keywords. Then papers were selected considering as sub searches age or pregnancy.

RESULTS AND DISCUSSION {#sec1-3}
======================

Considering the reports of ADRs in Calabria in 2012 (461 ADRs), only 17 (3.69%) were related to ketoprofen \[[Table 1](#T1){ref-type="table"}\], including ADRs in children and two in patients older than 65 years.

###### 

Clinical settings in which ketoprofen should be used with caution and those in which the use of ketoprofen is contraindicated

![](JPP-4-99-g001)

Most reports were due to the granular pharmaceutical form for oral solution/administration, with the exception of the three cases highlighted in the summary table below \[[Table 2](#T2){ref-type="table"}\], including an injectable formulation, a transdermal formulation, and a mouthwash.

###### 

ADRs of ketoprofen in Calabria in 2012

![](JPP-4-99-g002)

In 9 cases, the ADRs were reported by hospital physicians, in 4 cases by pharmacists, in 3 by the general practitioners, and in 1 case by medical specialists.

The most frequent reaction was urticaria (5 ADRs).

Of the 17 cases, the therapeutic indication observed in 7 cases (41.2%) was for the treatment of headache, in 6 cases (35.3%) for acute painful symptomatology, in 2 cases (11.8%) for the treatment of toothache; in the remainder of the cases, one for tonsillitis (5.9%) and one for knee pain (5.9%).

The gender distribution of the patients is 7 men and 10 women, mean age 46 years (exceptions are only one patient aged below 12 years and 2 patients older than 65 years).

Only one ADR was considered as serious:

An 11-year-old child was treated for toothache for a week with ketoprofen 80 mg/die (granules for oral solution) and required hospitalization for pancreatitis.

Starting from ADRs in Calabria, we reviewed the use and safety of this drug, especially in fragile categories (children, elderly, and pregnant women).

We have found it interesting to evaluate, through the study of literature, the use and safety of ketoprofen in classes of patients considered to be more fragile as children, pregnant, and the elderly. In fact, we consider that the under reporting in such fragile population might be due to the knowledge that ketoprofen might be used without indication (off-label).

Use of ketoprofen in children {#sec2-1}
-----------------------------

Ketoprofen has been widely used in the management of inflammatory and musculoskeletal conditions, pain, and fever in children and adults. It crosses the blood-brain barrier and therefore it has the potential to cause central analgesic effects. The pediatric use of ketoprofen has been investigated for the treatment of pain and fever, peri- and post-operative pain, and inflammatory pain conditions.\[[@ref4]\]

Kokki\[[@ref4]\] showed that drug exposure after a single intravenous dose is similar in children and adults and thus similar mg/kg bodyweight dosing may be used in children and adults. Ketoprofen has been investigated in children for the treatment of pain and fever, peri- and post-operative pain, and inflammatory pain conditions. Analgesic efficacy was similar with intravenous, intramuscular, or rectal routes of administration, but the oral administration just before surgery, was inferior to the intravenous administration in this setting. Most of the adverse events reported were mild and transient, and were similar to those observed with other NSAIDs. Long-term tolerability has not been yet fully established.\[[@ref4]\]

Kokki *et al*.\[[@ref5]\] studied 220 children in the age range 1 to 7 years, inclusive, who underwent adenoidectomy and investigated post-operative analgesic effect of low dose of ketoprofen (0.3 mg kg^−1^) without any further adverse effects or peri-operative bleeding. For adenoidectomy, intravenous ketoprofen provided superior post-operative analgesic efficacy compared with placebo. Most frequent side effects were nausea and vomiting, which were observed in 13% of patients.

Celebi *et al*.\[[@ref6]\] compared efficacy and side effects of ketoprofen, acetaminophen, and ibuprofen in 301 children, between 6 months and 14 years of age, presented to emergency room of 3 medical centers with the complaint of fever. The three drugs were similar in terms of efficacy, adverse effects, and compliance. The incidence of early vomiting in the ketoprofen group was 13.2%, similar to the data reported by Kokki *et al*.\[[@ref7]\]

Salonen *et al*.\[[@ref8]\] realized a prospective, longitudinal study in 102 children undergoing tonsillectomy to determine the safety and efficacy of ketoprofen in pain treatment after surgery. The main problem after tonsillectomy is the significant pain that may last 9 days or longer after surgery. Ketoprofen combined with paracetamol/codeine seems to provide sufficient analgesia.

Ruperto *et al*.\[[@ref9]\] conducted a study in 97 children aged 6 to 12 years, inclusive, with sore throat, which confirmed that paracetamol or ketoprofen, administered as a single oral dose, is a safe and effective treatment in children and it can be used without any special risks of analgesic drugs also in primary care.

Messeri *et al*.\[[@ref10]\] compared the analgesic effect of ketoprofen and acetaminophen in 85 children between the ages of 6 to 14 years, inclusive, who had minor surgical procedures and found that the analgesic effect of ketoprofen started earlier and lasted longer. No side effects related to the treatment were noted.

Sturkenboom *et al*.\[[@ref11]\] realized a retrospective cohort study (2000-2005) to provide an overview of drug use in children in three European countries: Italy, UK, and Netherlands. Ketoprofen was among the most prescribed drugs in Italy and in the UK. In the latter country, users were 86/1000, of whom 16 were between the ages of 2 and 11 years, inclusive, and 70 between 12 and 18 years, inclusive; in Italy, users were 362/1000, of whom 8 with less than 2 years and 354 between 2 and 11 years, inclusive. This confirms that the use of ketoprofen in Italy is greater than in other countries, even in the age in which it is contraindicated (off-label use).

In conclusion, from this data it seems that the use of ketoprofen in children might represent a safe and efficacious alternative, however, the under reporting in this age range must be reconsidered and attention must be paid to this off-label use.

Use of ketoprofen in pregnancy {#sec2-2}
------------------------------

There are no controlled data in human pregnancy about the use of ketoprofen.\[[@ref12]\] Animal studies failed to reveal evidence of embryotoxicity or teratogenicity except at doses which produced a significant maternal toxicity.\[[@ref13]\] When ketoprofen is used late in pregnancy, it may cause premature closure of the ductus arteriosus and may prolong labor and delivery.\[[@ref13]\] Ketoprofen is only recommended for use during pregnancy when benefits outweigh the risks. Ketoprofen has to be avoided in the last trimester of pregnancy and should not be used in the first two trimesters unless the potential benefit to the patient outweighs the potential risk to the fetus.

As weak acids, NSAIDs are excreted in small amounts into human breast milk with little risk for adverse effects in the suckling infant.\[[@ref14]\]

Llanas *et al*.\[[@ref15]\] reported of 11 neonates from 7 pregnancies, which were admitted because of ketoprofen-suspected adverse effects, where ketoprofen was administered to their mothers before delivery. It was reported that 10/11 neonates had renal dysfunction and in 3 cases it was lethal; 2 of the 11 developed cardiopulmonary complications and in 1 case it was lethal. Ketoprofen plasma concentration was found to be high in the first few hours of life in 3/6 patients.

A number of studies in which pregnancy outcome has been documented in the offspring of women treated during early pregnancy with various NSAIDs have been published.\[[@ref16][@ref17][@ref18][@ref19]\]

Based on these studies, it is not thought that NSAIDs are serious teratogens, but they may be associated with low risks for certain congenital malformations and possibly miscarriage. Despite the demonstrated lack of substantial teratogenic risk following first trimester exposure to NSAIDs, a number of risks have been documented when fetal exposure occurs later in pregnancy. Premature closure of the fetal ductus arteriosus with resultant pulmonary hypertension has been noted in association with the use of NSAIDs in the third trimester. Renal dysgenesis leading to oligohydramnios has been observed during the latter pregnancy period due to the exposure to indomethacin, ibuprofen, naproxen, ketoprofen, nimesulide, and piroxicam.\[[@ref19]\]

Use of ketoprofen in the elderly {#sec2-3}
--------------------------------

Elderly patients are at higher risk for side effects from medications.\[[@ref20]\] Aging changes pharmacodynamics and pharmacokinetics of drugs affecting choice, dosage, and frequency of administration of several drugs.\[[@ref21]\] Although life expectancy is gradually increasing in Western countries, the elderly continue to be excluded from participating in clinical trials. The drugs are mainly tested in subjects below 65 years old, but then are often used in elderly patients with multiple concomitant diseases.\[[@ref22]\]

The NSAIDs are often used in the elderly and may induce side effects. Safety of ketoprofen in the elderly was investigated by Le Loet.\[[@ref23]\] He has monitored the safety profile of ketoprofen in 19.880 patients older than 60 years of age, demonstrating good efficacy and tolerability. Side effects were observed in 15.3% of patients. The most frequent side effects were related to the gastrointestinal tract (13.5% of total patients --- ulcer and malena in 0.03%) and skin side effects in 0.7%.

Schattenkirchner has assessed the safety profile of ketoprofen over a 12-month treatment period in 823 patients aged ≥65 years (mean age: 72 years) with osteoarthritis or rheumatoid arthritis. At the end of the study, 302 patients (36.7%) had withdrawn from treatment for various reasons, including adverse reactions, inefficacy, and improvement, or had been lost to follow-up. A total of 314 patients (38.2%) experienced at least one adverse event during the study. Most side effects involved the digestive system (232 patients; 28.2%), the central nervous system (33 patients; 4.0%), or the cardiovascular system (26 patients; 3.2%); gastrointestinal adverse events like ulceration and bleeding (14 patients; 1.7%).\[[@ref24]\]

An adverse reaction can cause a disease that if not diagnosed as ADRs may lead to the use of a second drug to treat the disease. Prescribing cascade begins when an ADR is misinterpreted as a new clinical condition. The addition of a new drug puts the patient at risk of developing more adverse events related to the treatment, which was instead superfluous.\[[@ref25]\]

The elderly have an increased risk of developing iatrogenic pathologies often higher and more severe than in younger individuals. Drugs at risk of potentially serious reactions in the elderly are often the ones usually prescribed for treatment of chronic diseases. An example of interaction among drugs in the elderly in polytherapy is that of the Triple Whammy (TW): the interaction between angiotensin-converting enzyme inhibitors (or Angiotensin II Inhibitors --- Angiotensin II Receptor Blockers), diuretics, and NSAIDs/cox-2 inhibitors, which is characterized by RF. A prospective cohort study has been conducted on the entire population of Ferrara province to analyze patients aged ≥65 years in treatment with the drugs under study. A record linkage with the archive of admissions at the provincial level (SDO) was made and hospitalizations due to TW between 2009 and the first half of 2011 were evaluated, indicating that there is a risk of TW in the population treated with the Anatomical Therapeutic Chemical classification of drugs classes C09, C03, and M01.\[[@ref26]\]

It is necessary to conclude by presenting the safety profile of NSAIDs evaluated by Lapeyre-Mestre *et al*.\[[@ref27]\] Eight oral NSAIDs (aceclofenac, diclofenac, ketoprofen, meloxicam, naproxen, nimesulide, piroxicam, and tenoxicam) were evaluated using data reported through French pharmacovigilance system from 2002 to 2006, focusing on the reported rates of serious ADRs in the following system organ classes: gastrointestinal, hepatic, cutaneous, renal, and cardiovascular. Ketoprofen was associated with the highest cumulative reported rate of serious ADRs (0.78 cases per million defined daily doses). Most frequently reported serious ADRs were cutaneous, followed by gastrointestinal, hepatic, renal, and rarely, cardiovascular events. Most frequent serious ADRs reported with the selected oral NSAIDs are cutaneous, followed by gastrointestinal, hepatic, and renal events. The utmost risks for serious gastrointestinal, hepatic, cutaneous, and renal adverse events were linked, respectively, with ketoprofen, nimesulide, meloxicam, and tenoxicam compared with the other NSAIDs.

With the increase of cases of serious side effects related to the use of ketoprofen, several bodies of sanitary control at European level have taken steps to limit access to the drug (e.g., in Italy, now the medical NOT repeatable prescription --- RNR is required), or even in some cases it has been withdrawn from the market (e.g., in Spain and Finland). Although today, ketoprofen is considered a safer medication over nimesulide, we still need to have some thorough understanding of its uses, doses, and bounds, to avoid an underestimation of the risks or abuse done in good faith and not jeopardize their own health.
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